Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iguratimod in Primary Sjögren's Syndrome
NCT04981145Phase 4Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jan 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of iguratimod in primary Sjögren's syndrome, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Sjögren's Syndrome Responder Index 30 at 24 weeks. Started Jan 2022; status: recruiting.
02
Drugs
iguratimod
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NCT04981145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04981145.